Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

AERIE PHARMACEUTICA Form 4 March 17, 2014	ALS INC					
	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				PPROVAL 3235-0287	
Subject to Section 16. Form 4 or Form 5 Filed pu	Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940					
(Print or Type Responses)						
		er Name and Ticker or Trading E PHARMACEUTICALS ING]	5. Relationship of Reporting Person(s) to IssuerC (Check all applicable)			
(Last) (First) (C/O AERIE PHARMACEUTICALS, IN U.S. HIGHWAY 206, SUIT	(Month/ 03/13/2 C., 135	of Earliest Transaction Day/Year) 2014	Director X Officer (give below) Chief		6 Owner er (specify er	
(Street)		endment, Date Original onth/Day/Year)	Applicable Line) _X_ Form filed by C	or Joint/Group Filing(Check) by One Reporting Person by More than One Reporting		
BEDMINSTER, NJ 07921			Person		.pormg	
(City) (State)	(Zip) Tal	ole I - Non-Derivative Securities A	cquired, Disposed of	, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price	SecuritiesFBeneficially(IOwned(I	form: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate lin	e for each class of sec	Code V Amount (D) Price	or indirectly			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number orDerivative Securities Acquired (A Disposed o (Instr. 3, 4, 5)	A) or f (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy) <u>(1)</u>	\$ 20.7	03/13/2014		А	115,000		<u>(1)</u>	03/13/2024	Common Stock	115,000	
Reporting Owners											
Reporting Owner Name / Address Dir				Relationsh	ips						
		Director	10% Owner	Officer			Other				
LEVY BRIAN C/O AERIE PHARMACEUTICALS, INC. 135 U.S. HIGHWAY 206, SUITE 15 BEDMINSTER, NJ 07921		Chief Medical Officer									
Signa	tures										
/s/ Richard J. Rubino, Attorney-in-Fact for Brian Levy		03/1	7/2014								
**Signature of Reporting Person			Date								

Edgar Filing: AERIE PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on March 13, 2014 and is scheduled to vest with respect to 25% of the underlying shares on March 13, 2015, and thereafter in 36 equal installments on each monthly anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.